NEW YORK, Dec 12 - Diversa said Tuesday it had reached an agreement with Glaxo Wellcome to jointly research novel small molecules in Diversa’s PathwayLibraries.
Under the terms of the non-exclusive deal, Diversa and Glaxo Research and Development, a subsidiary of Glaxo Wellcome, will identify and screen molecules in the database for specific pharmaceutical activity.
Glaxo Wellcome will receive exclusive worldwide rights to molecules selected for commercialization. Diversa did not disclose financial terms of the deal.
Diversa's PathwayLibraries holds small molecule drug candidates produced by collections of gene pathways from environmental sources. Complex recombinant libraries are generated from uncultivated microorganisms with the company’s own methods for extracting DNA from the environment and by applying patented normalization methodologies.
The company said that its approach helps to speed up drug discovery and to identify gene products from the many microbes that remain unexplored.
" This collaboration with Diversa gives Glaxo Wellcome the potential to evaluate a new source of chemical diversity with the potential to generate novel leads for important therapeutic targets," said Allan Baxter, group discovery director at Glaxo Wellcome, said in a statement.
Earlier this month, Diversa said it had signed a “multi-year, cross-royalty” collaboration with Celera to sequence the genomes of extremophiles in its libraries.